Pancreatic Cancer Research

ResearcherUniversität UlmActive in the last 2 years

Bo Kong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5281-9603; OpenAlex author ID A5101725655, A5139755367. Sources: OpenAlex.

Their work

Papers
52 (first author 4, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
173
Papers, trials and grants by year

2011: 3 papers · 2012: 2 papers · 2013: none · 2014: 2 papers · 2015: 8 papers · 2016: 2 papers · 2017: 3 papers · 2018: 3 papers · 2019: 3 papers · 2020: 5 papers · 2021: 7 papers · 2022: 3 papers · 2023: none · 2024: 2 papers · 2025: 5 papers · 2026: 4 papers

Papers 50 of 52

  1. Pancreatic cancer induces B cell lineage plasticity via Pax5 inhibition to sustain immunosuppression. Co-author DOI 10.1038/s41420-026-03174-z↗
  2. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  3. Tumor Location and Preoperative Biliary Stenting Shape Gut Microbiome Diversity in Pancreatic Cancer. Co-author DOI 10.3390/cancers18162617↗
  4. Preoperative biliary stenting is associated with functional dysbiosis and impaired bile acid metabolism in pancreatic cancer - Impact of preoperative biliary s… Co-author DOI 10.64898/2026.05.19.719953↗
  5. ARP2/3 complex affects myofibroblast differentiation and migration in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ijc.35246↗
  6. Extracellular vesicles from pancreatic cancer and its tumour microenvironment promote increased Schwann cell migration. Co-author DOI 10.1038/s41416-024-02915-0↗
  7. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  8. The influence of clinical risk factors on the classification of human cancer-associated fibroblasts in PDAC and pancreatitis patients. Co-author DOI 10.1038/s44276-025-00150-5↗
  9. Pancreatic cancer patient-derived organoids capture therapy response and tumor evolution Co-author DOI 10.1101/2025.04.24.650216↗
  10. IFNα-induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. Co-author DOI 10.1016/j.celrep.2024.114088↗
  11. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  12. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  13. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  14. Loss of Heterozygosity for Kras G12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF-2α-c-Myc-Regulated Glutamine Metabolism. Co-author DOI 10.3390/ijms23126697↗
  15. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Co-author DOI 10.1038/s41392-021-00659-4↗
  16. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Last author DOI 10.1053/j.gastro.2021.07.030↗
  17. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer. Last author DOI 10.1080/14728222.2021.1857727↗
  18. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Co-author DOI 10.1097/cej.0000000000000588↗
  19. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  20. Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent man… Co-author DOI 10.1186/s13148-021-01016-6↗
  21. PPARγ/SOD2 Protects Against Mitochondrial ROS-Dependent Apoptosis via Inhibiting ATG4D-Mediated Mitophagy to Promote Pancreatic Cancer Proliferation. Co-author DOI 10.3389/fcell.2021.745554↗
  22. Loss of heterozygosity for Kras G12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbrc.2020.03.137↗
  23. CircRHOT1 mediated cell proliferation, apoptosis and invasion of pancreatic cancer cells by sponging miR-125a-3p. Co-author DOI 10.1111/jcmm.15572↗
  24. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Co-author DOI 10.1158/1055-9965.epi-19-1027↗
  25. ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism. Co-author DOI 10.3389/fonc.2020.00915↗
  26. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer. Co-author DOI 10.7150/thno.43093↗
  27. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Co-author DOI 10.1002/ijc.31866↗
  28. Long non-coding RNA HOTAIR promotes cancer cell energy metabolism in pancreatic adenocarcinoma by upregulating hexokinase-2. Co-author DOI 10.3892/ol.2019.10551↗
  29. AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis. Co-author DOI 10.7150/jca.28299↗
  30. Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.jcmgh.2018.07.003↗
  31. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Co-author DOI 10.1093/ije/dyx269↗
  32. KrasG12D-LOH promotes malignant biological behavior and energy metabolism of pancreatic ductal adenocarcinoma cells through the mTOR signaling pathway. Co-author DOI 10.4149/neo_2018_170224n142↗
  33. A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Co-author DOI 10.1093/annonc/mdx167↗
  34. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Co-author DOI 10.1136/gutjnl-2015-310442↗
  35. Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models. Co-author DOI 10.18632/oncotarget.15524↗
  36. Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.6717↗
  37. Should every patient with pancreatic cancer receive perioperative/neoadjuvant therapy? First author DOI 10.4103/0971-5851.195731↗
  38. Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.02.001↗
  39. A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels. Co-author DOI 10.1038/srep08109↗
  40. Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience. First author DOI 10.1186/s12893-015-0086-1↗
  41. Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0358-5↗
  42. Erratum to: Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0401-6↗
  43. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Co-author DOI 10.1245/s10434-015-4851-2↗
  44. Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer. Co-author DOI 10.18632/oncotarget.5168↗
  45. Strategies to improve the outcome in locally advanced pancreatic cancer. Co-author PMID 25658301↗
  46. The role of inflammation in pancreatic cancer. First author DOI 10.1007/978-3-0348-0837-8_6↗
  47. Re: proteomic mucin profiling for the identification of cystic precursors of pancreatic cancer. First author DOI 10.1093/jnci/dju263↗
  48. Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype. Co-author DOI 10.1186/1476-4598-11-19↗
  49. The impact of the activated stroma on pancreatic ductal adenocarcinoma biology and therapy resistance. Co-author DOI 10.2174/156652412799218921↗
  50. Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Co-author DOI 10.1002/ijc.25898↗

Closest collaborators

The 25 strongest of 173 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christoph W. Michalski · 29 shared papers, 2011–2026 · strength 2.28
  2. Jorg H. Kleeff · 27 shared papers, 2011–2025 · strength 1.69
  3. Helmut Frieß · 9 shared papers, 2011–2025 · strength 0.77
  4. Peilin Huang · 7 shared papers, 2018–2022 · strength 0.73
  5. Mingyue Hu · 6 shared papers, 2018–2022 · strength 0.67
  6. Helmut Friess · 10 shared papers, 2011–2022 · strength 0.64
  7. Yu Ma · 5 shared papers, 2019–2022 · strength 0.60
  8. Sunkai Ling · 5 shared papers, 2018–2022 · strength 0.58
  9. Linda Sharp · 8 shared papers, 2017–2024 · strength 0.58
  10. Luis Muñoz‐Bellvís · 8 shared papers, 2017–2024 · strength 0.58
  11. Núria Malats · 8 shared papers, 2017–2024 · strength 0.58
  12. J. Enrique Domínguez‐Muñoz · 8 shared papers, 2017–2024 · strength 0.58
  13. Alfredo Carrato · 8 shared papers, 2017–2024 · strength 0.58
  14. William Greenhalf · 8 shared papers, 2017–2024 · strength 0.58
  15. Tatjana Crnogorac‐Jurcevic · 8 shared papers, 2017–2024 · strength 0.58
  16. Thomas Mathias Gress · 8 shared papers, 2017–2024 · strength 0.58
  17. Aldo Scarpa · 8 shared papers, 2017–2024 · strength 0.58
  18. Eithne Costello · 8 shared papers, 2017–2024 · strength 0.58
  19. Francisco X. Real · 8 shared papers, 2017–2024 · strength 0.58
  20. Shanshan Shen · 6 shared papers, 2018–2021 · strength 0.57
  21. Thomas P. Hank · 2 shared papers, 2026 · strength 0.47
  22. Ingmar Florin Rompen · 2 shared papers, 2026 · strength 0.47
  23. Marionna Cathomas · 2 shared papers, 2026 · strength 0.47
  24. Jonathan M. Harnoss · 2 shared papers, 2026 · strength 0.47
  25. Rogier Aäron Gaiser · 2 shared papers, 2026 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.